Session » Antiphospholipid Syndrome Poster

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 134

‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort

9:00AM-11:00AM: Abstract Number: 135

Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations

9:00AM-11:00AM: Abstract Number: 131

Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population

9:00AM-11:00AM: Abstract Number: 132

Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 133

Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 126

Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS

9:00AM-11:00AM: Abstract Number: 142

Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities

9:00AM-11:00AM: Abstract Number: 139

Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE

9:00AM-11:00AM: Abstract Number: 144

Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype

9:00AM-11:00AM: Abstract Number: 143

Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 145

Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results

9:00AM-11:00AM: Abstract Number: 140

Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis

9:00AM-11:00AM: Abstract Number: 127

Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 136

Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients

9:00AM-11:00AM: Abstract Number: 130

Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting

9:00AM-11:00AM: Abstract Number: 128

Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis

9:00AM-11:00AM: Abstract Number: 141

Pregnancy in Antiphospholipid Syndrome: Outcomes and Risk Factors – Data from a Portuguese Multidisclinary Unit

9:00AM-11:00AM: Abstract Number: 138

Relationship Between Recurrent Thrombosis and the Antiphospholipid Antibodies Profile in a Cohort of Patients with Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 129

Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile

9:00AM-11:00AM: Abstract Number: 137

The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].